Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022
Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on August 16, 2022, at 8:30 a.m. ET to discuss its Q2 financial results and provide a business overview.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on August 16, 2022, at 8:30 a.m. ET to discuss its Q2 financial results and provide a business overview. The call can be accessed by calling (833) 630-1956 domestically or (412) 317-1837 internationally. Additionally, a live audio webcast will be available on the company's website, with an archived version posted two hours afterward. Bio-Path is focused on developing DNAbilize®, a proprietary RNAi nanoparticle technology, targeting cancer therapies.
Positive
- Live conference call scheduled for August 16, 2022, indicating transparency and engagement with investors.
- Focus on advancing clinical programs, including BP1001 in Phase 2 for blood cancers and upcoming Phase 1 studies for BP1001-A.
Negative
- None.
Details
News Market Reaction – BPTH
The recorded move for BPTH in the trading session of this news was -2.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 16, 2022 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2022 and to provide a business overview.
To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.